{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:41:17Z","timestamp":1768311677206,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Array BioPharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10637-018-0600-2","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T01:59:21Z","timestamp":1526954361000},"page":"1037-1043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer"],"prefix":"10.1007","volume":"36","author":[{"given":"R. S.","family":"Finn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Javle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"B. R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Weekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. N.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Chavira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Christy-Bittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","volume":"366","author":"SA Khan","year":"2005","unstructured":"Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303\u20131314","journal-title":"Lancet"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cld.337","volume":"3","author":"S Sadeghi","year":"2014","unstructured":"Sadeghi S, Finn RS (2014) Systemic therapy for cholangiocarcinoma. Clin Liver Dis 3:86\u201389","journal-title":"Clin Liver Dis"},{"key":"600_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000658-199803000-00012","volume":"227","author":"JS Goydos","year":"1998","unstructured":"Goydos JS, Brumfield AM, Frezza E et al (1998) Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227:398\u2013404","journal-title":"Ann Surg"},{"key":"600_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/hep.510300522","volume":"30","author":"J Park","year":"1999","unstructured":"Park J, Tadlock L, Gores GJ, Patel T (1999) Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30:1128\u20131133","journal-title":"Hepatology"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954","journal-title":"Nature"},{"key":"600_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.1779","volume":"206","author":"K Nakazawa","year":"2005","unstructured":"Nakazawa K, Dobashi Y, Suzuki S et al (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206:356\u2013365","journal-title":"J Pathol"},{"key":"600_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2003.08.004","volume":"50","author":"A Bennasroune","year":"2004","unstructured":"Bennasroune A, Gardin A, Aunis D et al (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 50:23\u201338","journal-title":"Crit Rev Oncol Hematol"},{"key":"600_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.leu.2401657","volume":"14","author":"JA McCubrey","year":"2000","unstructured":"McCubrey JA, May WS, Duronio V, Mufson A (2000) Serine\/threonine phosphorylation in cytokine signal transduction. Leukemia 14:9\u201321","journal-title":"Leukemia"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","volume":"29","author":"T Bekaii-Saab","year":"2011","unstructured":"Bekaii-Saab T, Phelps MA, Li X et al (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357\u20132363","journal-title":"J Clin Oncol"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/bjc.2012.144","volume":"106","author":"CM Prado","year":"2012","unstructured":"Prado CM, Bekaii-Saab T, Doyle LA et al (2012) Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 106:1583\u20131586","journal-title":"Br J Cancer"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell JC, Javle M, Bekaii-Saab TS et al (2017) A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br J Cancer 116:575\u2013583","journal-title":"Br J Cancer"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"600_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","volume":"97","author":"W Shen","year":"2004","unstructured":"Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97:2333\u20132338","journal-title":"J Appl Physiol (1985)"},{"key":"600_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/SPC.0b013e328331124a","volume":"3","author":"CM Prado","year":"2009","unstructured":"Prado CM, Birdsell LA, Baracos VE (2009) The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3:269\u2013275","journal-title":"Curr Opin Support Palliat Care"},{"key":"600_CR16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3945\/ajcn.113.060228","volume":"98","author":"CM Prado","year":"2013","unstructured":"Prado CM, Sawyer MB, Ghosh S et al (2013) Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98:1012\u20131019","journal-title":"Am J Clin Nutr"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","volume":"70","author":"JR Dry","year":"2010","unstructured":"Dry JR, Pavey S, Pratilas CA et al (2010) Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70:2264\u20132273","journal-title":"Cancer Res"},{"key":"600_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/jhep.2003.50200","volume":"37","author":"GJ Gores","year":"2003","unstructured":"Gores GJ (2003) Cholangiocarcinoma: current concepts and insights. Hepatology 37:961\u2013969","journal-title":"Hepatology"},{"key":"600_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-1-60327-530-9_15","volume":"512","author":"NN Mon","year":"2009","unstructured":"Mon NN, Kokuryo T, Hamaguchi M (2009) Inflammation and tumor progression: a lesson from TNF-alpha-dependent FAK signaling in cholangiocarcinoma. Methods Mol Biol 512:279\u2013293","journal-title":"Methods Mol Biol"},{"key":"600_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1440-1746.1994.tb01275.x","volume":"9","author":"K Okada","year":"1994","unstructured":"Okada K, Shimizu Y, Nambu S et al (1994) Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9:462\u2013467","journal-title":"J Gastroenterol Hepatol"},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/jhbp.126","volume":"21","author":"K Maemura","year":"2014","unstructured":"Maemura K, Natsugoe S, Takao S (2014) Molecular mechanism of cholangiocarcinoma carcinogenesis. J Hepatobiliary Pancreat Sci 21:754\u2013760","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2007-03-081240","volume":"110","author":"YT Tai","year":"2007","unstructured":"Tai YT, Fulciniti M, Hideshima T et al (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110:1656\u20131663","journal-title":"Blood"},{"key":"600_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-7-45","volume":"7","author":"D Zhang","year":"2007","unstructured":"Zhang D, Zheng H, Zhou Y et al (2007) Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer 7:45","journal-title":"BMC Cancer"},{"key":"600_CR24","first-page":"113","volume":"38","author":"D Zhang","year":"2008","unstructured":"Zhang D, Zhou Y, Wu L et al (2008) Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann Clin Lab Sci 38:113\u2013119","journal-title":"Ann Clin Lab Sci"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0600-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:26:07Z","timestamp":1678559167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0600-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"9 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. R. S. Finn is a consultant for Bayer, Novartis, Pfizer Inc., Bristol-Myers Squibb. Dr. D. H. Ahn is a consultant for Merrimack. Dr. A. Patnaik receives institutional research funding from Array BioPharma Inc. R. Chavira, J. Christy-Bittel, and Dr. Barrett are current or former employees, and may own stock in, Array BioPharma Inc. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}